BioSpace News Archive

Clozapine drug refers to an atypical antipsychotic medication. It is majorly utilized to relieve the symptoms of schizophrenia.

The number of cardiac-related issues such as arrhythmia, cardiac arrest, valve blocks, and heart attack is rising presently.

Development of assays that feature as rapid medical diagnostics attracts groundswell of interest of healthcare systems worldwide.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces, effective March 1, 2021, Ms. Lisa Deschamps has joined the board as a Non-Executive Director.

MH Guide/BRCA and MH Guide/Mendel will assist doctors and human geneticists in making decisions about gene variant pathogenicity.

CN Bio, a leading developer of single and multi-organ microphysiological systems, otherwise known as organ-on-a-chip, announced it has received a grant from Innovate UK, the UK’s innovation agency, to develop human-relevant MPS to advance investigations into SARS-CoV-2 infection.

InspireMD, Inc., the developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by carotid artery disease, announces it will report fiscal fourth quarter and year-end 2020 financial results on Tuesday, March 9, 2021 before the market opens.

Itamar Medical Ltd., a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders, reported unaudited financial results for the fourth quarter and full year 2020 and provided full year 2021 guidance.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, announced that Snehal Patel, CEO of Greenwich LifeSciences, will participate in multiple virtual investor conferences in March 2021.

NanoViricides, Inc. a leader in the development of highly effective antiviral therapies based on a novel nanomedicine technology platform, reported on the strong pan-coronavirus effectiveness of its two COVID-19 clinical drug candidates for which the Company is preparing a pre-IND application.